Next & Bio eyes drug tailoring with human organ-modeling organoids
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
An organoid is a simplified version of an organ produced in vitro in three dimensions and this can be used to model cancer behavior during disease progression and get insights for personalized medicine, explained CEO Lee Hyun-sook.
Lee who founded Next & Bio in 2018 is a life science professor at Seoul National University and basic molecular biologist who has studied the mechanisms of cancer pathogenesis.
Lee was studying genetically engineered mice to see how normal cells turn into cancer cells in her lab but felt the limit in actual anatomy of cancer progression. What came to her mind as a solution was organoids.
“As I conducted research using organoids, I saw the potential for many business opportunities. For example, we can make organoids of pancreatic cancer patients and conduct an efficacy test of cancer drugs to identify the best regimen for patients,” Lee explained.
Next & Bio is a platform company that uses organoids to help develop novel therapies and provide accurate diagnosis and personalized medicine services.
In the medical and scientific community, there is a view that organoids would replace animal tests in future drug development.
Drug candidates evaluated for toxicity and efficacy based on organoid trials will go through a fast-track program for regulatory authorization. However, a relevant system should be in place first to support this change.
“We are working on domestic guidelines in cooperation with the Ministry of Food and Drug Safety, while participating in the establishment of OECD guidelines together with the Korea Institute of Science and Technology (KIST)’s European Institute,” Lee said.
According to market data, the global organoid market is worth about 1 trillion won ($771 million) and is expected to grow to about 4 trillion won in 2027.
Kolmar Korea, a manufacturer of cosmetics, skin care and personal care products, became the largest shareholder of Next & Bio in December last year by acquiring a 40 percent stake.
“As a platform company, Next & Bio will continue to expand markets through collaboration with various pharmaceutical companies and hospitals as well as Kolmar Korea, contributing to the growth of the Korean healthcare market,” Lee added.
[ㄏ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Soccer player Son Heung-min’s NOS7 items reselling at premium - Pulse by Maeil Business News Korea
- Stock and corporate performance moves the opposite direction for Korean Inc. - Pulse by Maeil Business News Korea
- LG to invest $115.8 mn over 3 years to groom startups through Superstart - Pulse by Maeil Business News Korea
- S. Korea’s private sector debt-to-GDP ratio falls slightly to 219% in Q1 - Pulse by Maeil Business News Korea
- KT beats the 3-mo bear run in Korean stock market to gain 26% - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- K방산 아킬레스건은 [K-방산 : New Dream]
- NCT 태일, 불미스러운 일로 팀 탈퇴…SM “엄중함 인지”[공식입장][전문] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이